-+ 0.00%
-+ 0.00%
-+ 0.00%

Benitec to present interim Phase 1b/2a BB-301 OPMD trial results at ASGCT meeting

PUBT·04/28/2026 11:03:40
Listen to the news
Benitec to present interim Phase 1b/2a BB-301 OPMD trial results at ASGCT meeting
  • Benitec Biopharma scheduled oral presentation of interim results from ongoing Phase 1b/2a first-in-human BB-301 study in oculopharyngeal muscular dystrophy with moderate dysphagia at 2026 ASGCT meeting on May 15, 2026.
  • Update will include 12-month follow-up for first four low-dose Cohort 1 completers, with one patient tracked out to 24 months.
  • Company reported continued durable improvements in low-dose group.
  • Interim readout will also cover first high-dose Cohort 2 patient.
  • Benitec positioned BB-301 as only clinical-stage therapeutic in development targeting dysphagia in patients diagnosed with OPMD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604280700PRIMZONEFULLFEED9708003) on April 28, 2026, and is solely responsible for the information contained therein.